These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6433471)

  • 1. Production of antihemophilic factor in France.
    Allain JP
    Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471
    [No Abstract]   [Full Text] [Related]  

  • 2. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of facoor VIII and factor IX concentrates during surgery.
    George JN; Breckenridge RT
    JAMA; 1970 Nov; 214(9):1673-6. PubMed ID: 5536529
    [No Abstract]   [Full Text] [Related]  

  • 4. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 6. Side effects of substitution therapy.
    Aledort LM
    Scand J Haematol Suppl; 1984; 40():331-3. PubMed ID: 6433459
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 8. Issues in making a therapeutic choice: recombinant and/or human-derived products.
    Aledort LM
    Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemophilia A and B.
    Shearin-Patterson T; Davidson EJ
    JAAPA; 2013 Apr; 26(4):49. PubMed ID: 23610840
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E; Shapiro AD; Waters J; Astermark J
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract]   [Full Text] [Related]  

  • 12. [Principles of modern therapy for hemophilia A and B in childhood].
    Ströder J; Ambs E
    Dtsch Med Wochenschr; 1968 Mar; 93(12):539-41. PubMed ID: 5639667
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 15. Overview of hemophilia.
    Sergis-Deavenport E; Miller R; Gomperts E
    Issues Compr Pediatr Nurs; 1983; 6(5-6):317-28. PubMed ID: 6421781
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: Blood fractions for haemophilia.
    Aledort LM
    Lancet; 1974 Dec; 2(7894):1452. PubMed ID: 4140363
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral solutions.
    Dolgin E
    Sci Am; 2015 Jan; 312(1):S12-3. PubMed ID: 25597119
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor VIII production and usage in Hungary.
    Elödi S; Hollán SR
    Scand J Haematol Suppl; 1984; 40():491-7. PubMed ID: 6433470
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].
    Medarde A; Ayesa C; Alfonso L; Muñóz A
    Sangre (Barc); 1979; 24(5-C):942-6. PubMed ID: 121170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.